The FDA approved belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor, for adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas or pancreatic neuroendocrine tumors (pNETs) not requiring immediate surgery.
“The approval of a nonsurgical treatment option is meaningful for helping patients with certain types of VHL-associated tumors,” said Ramaprasad Srinivasan, MD, PhD, the